Info@ThinkPinkRocks.com

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service’s National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

View article:
Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Share

Leave a Reply

Solve : *
20 + 22 =